open access

Vol 72, No 2 (2021)
Clinical vignette
Submitted: 2020-12-30
Accepted: 2021-01-06
Early publication date: 2021-01-19
Get Citation

Efficacy of multimodal anticancer therapy in the course of pancreatic neuroendocrine carcinoma

Helena Zwinczewska12, Marta Opalinska2, Anna Sowa-Staszczak21, Anna Kurzynska21, Agnieszka Stefanska2, Alicja Hubalewska-Dydejczyk21
DOI: 10.5603/EP.a2021.0005
·
Pubmed: 33619719
·
Endokrynol Pol 2021;72(2):183-184.
Affiliations
  1. Department of Endocrinology, University Hospital, Krakow, Poland
  2. Jagiellonian University Medical College, Krakow, Poland

open access

Vol 72, No 2 (2021)
Clinical Vignette
Submitted: 2020-12-30
Accepted: 2021-01-06
Early publication date: 2021-01-19

Abstract

Not required for Clinical Vignette.

Abstract

Not required for Clinical Vignette.

Get Citation

Keywords

neuroendocrine tumours; PRRT; pNEC; somatostatin analogue

About this article
Title

Efficacy of multimodal anticancer therapy in the course of pancreatic neuroendocrine carcinoma

Journal

Endokrynologia Polska

Issue

Vol 72, No 2 (2021)

Article type

Clinical vignette

Pages

183-184

Early publication date

2021-01-19

Page views

570

Article views/downloads

260

DOI

10.5603/EP.a2021.0005

Pubmed

33619719

Bibliographic record

Endokrynol Pol 2021;72(2):183-184.

Keywords

neuroendocrine tumours
PRRT
pNEC
somatostatin analogue

Authors

Helena Zwinczewska
Marta Opalinska
Anna Sowa-Staszczak
Anna Kurzynska
Agnieszka Stefanska
Alicja Hubalewska-Dydejczyk

References (6)
  1. Zhang MY, He Du, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol. 2020; 12(7): 705–718.
  2. Lokesh KN, Anand A, Lakshmaiah KC, et al. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience. South Asian J Cancer. 2018; 7(3): 207–209.
  3. Lorenzoni A, Capozza A, Artale S, et al. Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. Clin Nucl Med. 2018; 43(7): 506–508.
  4. Alese OB, Jiang R, Shaib W, et al. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2020; 25(5): e877.
  5. Rogowski W, Wachuła E, Gorzelak A, et al. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. Endokrynol Pol. 2019; 70(4): 313–317.
  6. Montanier N, Joubert-Zakeyh J, Pétorin C, et al. The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. Medicine (Baltimore). 2017; 96(6): e6062.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl